Soleno Therapeutics Inc (SLNO) — Capital Reinvestment Ratio

Latest as of March 2026: 0.00x

Soleno Therapeutics Inc (SLNO) has a Capital Reinvestment Ratio of 0.00x as of March 2026, meaning it reinvests 0% of its operating cash flow ($25.98 Million) in capital expenditures ($40.00K). See Soleno Therapeutics Inc net asset quality index to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

$25.98 Million
USD

Capital Expenditures

$40.00K
USD

Data as of

Mar 2026
Most recent filing

Soleno Therapeutics Inc Capital Reinvestment Ratio (2025–2025)

This chart tracks Soleno Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. Check how aggressively does Soleno Therapeutics Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Soleno Therapeutics Inc (2025–2025)

Year-by-year Capital Reinvestment Ratio for Soleno Therapeutics Inc from 2025 to 2025. For live market cap and broader valuation context, see Soleno Therapeutics Inc market cap and net worth.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2025 0.00x $46.80 Million $73.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow